Does Florida Blue (Blue Cross Blue Shield of Florida) Cover Eliquis?

What Is Eliquis and Why Is It Prescribed?

Eliquis (apixaban) is an oral direct factor Xa inhibitor approved by the FDA on December 28, 2012. It carries four distinct FDA indications that are relevant to Florida Blue coverage decisions: stroke and systemic embolism risk reduction in nonvalvular atrial fibrillation (AF), treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), reduction of recurrent DVT/PE risk, and prophylaxis of DVT following hip or knee replacement surgery. [1]

Clinical Evidence Behind the Prescriptions

The evidence base for apixaban is extensive. The ARISTOTLE trial (N=18,201) found apixaban reduced stroke or systemic embolism by 21% relative to warfarin (1.27% vs. 1.60% per year; P<0.001) and reduced major bleeding by 31% (2.13% vs. 3.09% per year; P<0.001) in patients with nonvalvular AF. [2] That bleeding advantage over warfarin is a primary reason physicians and guidelines favor apixaban when patients have higher hemorrhagic risk.

The AMPLIFY trial (N=5,395) compared apixaban with conventional therapy (enoxaparin followed by warfarin) for acute DVT and PE. Apixaban produced a 16% relative reduction in the primary efficacy outcome (2.3% vs. 2.7%) with a statistically significant 69% reduction in major bleeding (0.6% vs. 1.8%; P<0.001). [3] These results underpin the American College of Cardiology and American Heart Association guidelines recommending direct oral anticoagulants (DOACs) over vitamin K antagonists for most AF and VTE patients. [4]

Where Apixaban Sits in Current Treatment Guidelines

The 2023 ACC/AHA Atrial Fibrillation Guideline gives a Class I recommendation for oral anticoagulation in patients with AF and a CHA2DS2-VASc score of 2 or higher in men or 3 or higher in women, with DOACs preferred over warfarin in most patients. [4] The guideline lists apixaban, rivaroxaban, dabigatran, and edoxaban as the four approved DOAC options.

Because apixaban is a brand-name drug with no FDA-approved generic, insurers including Florida Blue place it in mid-to-high formulary tiers. Understanding that placement is essential before filling a prescription.

How Florida Blue Organizes Its Drug Formulary

Florida Blue uses a tiered formulary structure across all plan types: individual and family (ACA marketplace), employer-sponsored group plans, and Medicare Advantage plans. [5] Each tier carries a different cost-sharing level.

Tier Definitions on Typical Florida Blue Commercial Plans

• Tier 1: Generic drugs. Lowest copay, often $5, $15.
• Tier 2: Preferred generic or low-cost brand. Copay roughly $20, $35.
• Tier 3: Preferred brand. Copay roughly $50, $75 after deductible.
• Tier 4: Non-preferred brand. Copay roughly $80, $110 after deductible.
• Tier 5 (specialty): High-cost specialty drugs. Coinsurance often 20 to 33%.

Eliquis typically appears at Tier 3 or Tier 4 on Florida Blue commercial formularies. The exact tier can differ by plan year, by whether you are on a marketplace plan versus an employer plan, and by the specific formulary document your plan uses. Always verify by logging in to your Florida Blue member portal or calling the pharmacy benefits number on your insurance card.

How Medicare Advantage Plans Tier Eliquis

Florida Blue administers several Medicare Advantage plans (including BlueMedicare HMO and BlueMedicare PPO products). On Medicare Advantage formularies, Eliquis often appears in Stage 3 (preferred brand) or Stage 4 (non-preferred brand) tiers. [6] In the initial coverage phase, you may pay a flat copay of $40, $100 per fill. In the coverage gap (formerly the "donut hole"), your cost-sharing may increase. Once you reach the catastrophic coverage phase (out-of-pocket threshold set at $2,000 for 2025 under the Inflation Reduction Act Medicare drug price reforms), your cost drops to $0 copay for the rest of the year. [7]

The Centers for Medicare and Medicaid Services requires all Medicare Part D and Medicare Advantage formularies to include at least two drugs in each therapeutic class. All major Medicare Advantage formularies, including Florida Blue's, cover at least one DOAC for AF. Whether that DOAC is apixaban or an alternative (rivaroxaban, dabigatran) depends on the specific plan's negotiated contracts for that year.

Prior Authorization: The Most Common Coverage Barrier

Prior authorization (PA) is the single largest obstacle Florida Blue members face when filling an Eliquis prescription. Prior authorization means the insurer requires clinical documentation before approving coverage.

What Florida Blue Typically Requires

For Eliquis, Florida Blue PA criteria commonly include:

1. A confirmed diagnosis matching an FDA-approved indication (AF, DVT, PE, or joint replacement prophylaxis) with supporting documentation such as an ECG for AF or imaging for DVT/PE.
2. Documentation that the prescribing physician has considered alternatives, or in some cases, evidence of an intolerance to warfarin (e.g., labile INR, documented bleeding, drug-drug interaction). [8]
3. For recurrent VTE prevention: prior treatment course for the index DVT/PE event.

The FDA label states that apixaban's labeled dose for AF is 5 mg twice daily (or 2.5 mg twice daily if two of three criteria apply: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher). [1] PA requests must match the dose to the indication and patient characteristics.

Step Therapy Requirements

Some Florida Blue group plans include a step-therapy (fail-first) requirement. This means the plan may require that a patient try warfarin or another DOAC first, at a lower tier, before it will authorize Eliquis. Step therapy has been criticized in the medical literature: a 2019 analysis published in the American Journal of Managed Care found that step therapy delays for anticoagulants were associated with increased rates of stroke and hospitalization. [9]

Florida law (Florida Statutes Section 627.42393) requires insurers to grant a step-therapy override when a patient's physician certifies that the required first-step drug is contraindicated, has already been tried and failed, or would cause harm. [10] If your Florida Blue plan imposes a step-therapy requirement for Eliquis, your prescriber can submit an override request citing this statute.

Submitting a Prior Authorization Request

Your prescriber's office initiates a PA by submitting clinical notes, the diagnosis code (e.g., ICD-10 I48.0 for paroxysmal AF), and a completed PA form to Florida Blue's pharmacy department. Florida Blue's standard PA turnaround is up to 72 hours for non-urgent requests and 24 hours for urgent clinical situations. [11] Confirm these timelines directly with Florida Blue, as plan-specific rules apply.

The HealthRX pharmacy team has developed the following PA readiness checklist specifically for Eliquis submissions to Florida Blue:

Eliquis PA Readiness Checklist (Florida Blue)

• Confirmed ICD-10 diagnosis code linked to an FDA-approved Eliquis indication
• Supporting diagnostic documentation (12-lead ECG, Holter, compression ultrasound, or CT pulmonary angiography as appropriate)
• CHA2DS2-VASc score documented for AF patients (score 2+ for men, 3+ for women triggers Class I guideline recommendation) [4]
• Renal function (serum creatinine or eGFR) to justify dose selection
• Documentation of warfarin intolerance or contraindication if step therapy applies
• Bleeding risk assessment (HAS-BLED score or equivalent)
• Prescriber's direct contact information for peer-to-peer review if denied

What Eliquis Costs Without or With Florida Blue Coverage

Understanding the actual dollar figures helps members plan and negotiate.

List Price vs. Negotiated Price

The average wholesale price (AWP) for Eliquis 5 mg, 60 tablets (a 30-day supply at twice-daily dosing) is approximately $590, $640. Florida Blue negotiates a lower contracted rate with its pharmacy benefit manager, so the "allowed amount" is typically lower. After your deductible, you pay a Tier 3 or Tier 4 copay against that contracted rate, not the AWP. [12]

The Bristol-Myers Squibb / Pfizer Copay Card

For commercially insured patients who are not enrolled in Medicare, Medicaid, or any other federal or state health program, Bristol-Myers Squibb and Pfizer offer the Eliquis 360 Support copay assistance program. [13] Eligible patients may pay as little as $10 per month (up to a defined annual benefit cap, which has historically been $6,400 per year). This card is applied at the pharmacy counter and can dramatically reduce out-of-pocket costs even when Eliquis is on a high formulary tier.

Medicare beneficiaries are not eligible for manufacturer copay cards under federal anti-kickback regulations. Medicare Advantage enrollees on Florida Blue plans should instead look into the Extra Help / Low Income Subsidy (LIS) program administered by the Social Security Administration, which can reduce drug costs significantly. [14]

High-Deductible Plan Members

If your Florida Blue plan has a deductible (common in HDHP or HSA-eligible plans), you pay the full contracted price for Eliquis until your deductible is met. That can mean several hundred dollars per fill early in the plan year. Using an HSA to pay this cost is permitted under IRS rules for qualified medical expenses.

How to Appeal a Florida Blue Eliquis Denial

A denial is not final. Florida Blue members have multiple appeal options.

Internal Appeal

File a written internal appeal within 180 days of receiving the denial notice. Include your prescriber's clinical notes, the ARISTOTLE or AMPLIFY trial data if relevant, and a letter from your physician explaining why Eliquis is medically necessary rather than a therapeutic alternative. Florida Blue must respond within 30 days for standard pharmacy appeals and 72 hours for expedited (urgent) cases. [11]

A direct quote from the 2023 ACC/AHA AF guideline is useful here: "For patients with AF, with the exception of those with moderate-to-severe mitral stenosis or a mechanical heart valve, DOACs are recommended over warfarin." [4] This statement supports the argument that defaulting to warfarin fails to meet current standard of care for most AF patients.

External Independent Review

If the internal appeal is denied, Florida Blue members may request an external independent review through the Florida Department of Financial Services. The external reviewer is an independent organization contracted by the state, not Florida Blue, and its decision is binding on the insurer. [15] Federal law (the Affordable Care Act, codified at 42 U.S.C. Section 300gg-19) requires health plans to provide this external review option. [16]

Formulary Exception

Separately from the PA process, you may request a formulary exception asking Florida Blue to cover Eliquis at a lower cost-sharing tier. This requires documentation that the drugs on the lower tiers are medically inappropriate for you. For Medicare Advantage members, the formulary exception process is governed by CMS regulations at 42 CFR Part 423. [6]

Comparing Eliquis to Covered Alternatives on Florida Blue Formularies

Florida Blue formularies generally place other anticoagulants on different tiers. Understanding where each drug sits helps your prescribing physician have an informed conversation about alternatives.

Warfarin (Generic)

Warfarin is a Tier 1 generic on virtually all Florida Blue formularies. Monthly cost after deductible: $5, $15. However, warfarin requires regular INR monitoring, has numerous drug and food interactions, and carries a narrower therapeutic index. The ARISTOTLE trial demonstrated apixaban's superiority over warfarin for both stroke prevention and major bleeding in AF patients. [2] For many patients, the clinical case for apixaban over warfarin is strong despite the cost difference.

Rivaroxaban (Xarelto)

Rivaroxaban is also a brand-name DOAC (factor Xa inhibitor) with no approved generic. It may appear on a different tier than apixaban depending on which DOAC Florida Blue has negotiated better pricing for in a given plan year. In the ROCKET-AF trial (N=14,264), rivaroxaban was non-inferior to warfarin for stroke prevention in AF (1.7% vs. 2.2% per year in the per-protocol analysis). [17] Some Florida Blue plans place rivaroxaban at a lower preferred tier than apixaban; others do the reverse. Check the current formulary.

Dabigatran (Pradaxa)

Dabigatran is a direct thrombin inhibitor. In the RE-LY trial (N=18,113), dabigatran 150 mg twice daily was superior to warfarin for stroke prevention in AF (1.11% vs. 1.69% per year; P<0.001) but was associated with higher rates of gastrointestinal bleeding. [18] Dabigatran has an approved reversal agent (idarucizumab/Praxbind), as does apixaban (andexanet alfa/Andexxa, FDA-approved May 2018). [19]

Edoxaban (Savaysa)

Edoxaban is a once-daily factor Xa inhibitor. In ENGAGE AF-TIMI 48 (N=21,105), high-dose edoxaban (60 mg once daily) was non-inferior to warfarin for stroke prevention and caused significantly less major bleeding (2.75% vs. 3.43% per year; P<0.001). [20] Edoxaban has a labeling restriction requiring it be preceded by 5 to 10 days of parenteral anticoagulation for VTE treatment, which limits its use in that setting.

Your prescriber should choose among these options based on your renal function, bleeding history, drug interactions, dosing preference, and the specific formulary tier structure of your Florida Blue plan.

Special Populations and Coverage Considerations

Patients with Chronic Kidney Disease

Apixaban requires a dose adjustment (2.5 mg twice daily) if two of three criteria apply: age 80 or older, weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. [1] Patients on dialysis are generally not candidates for DOACs; warfarin remains standard in end-stage renal disease for AF, though evidence from small trials and observational data has led some specialists to use apixaban off-label in dialysis patients with individualized risk assessment. [21] Florida Blue PA forms for dialysis patients on Eliquis require additional documentation.

Patients Following Orthopedic Surgery

For DVT prophylaxis after knee or hip replacement, Eliquis is FDA-labeled at 2.5 mg twice daily for 12 days (knee) or 35 days (hip). [1] Coverage for this short-course use is generally straightforward if the PA specifies the surgical date, procedure, and duration. The 2012 ADVANCE-3 trial (N=5,407) found apixaban 2.5 mg twice daily reduced total VTE and all-cause mortality by 64% versus enoxaparin 40 mg once daily after hip replacement (1.4% vs. 3.9%; P<0.001). [22]

Cancer-Associated Thrombosis

Apixaban is used off-label (and in some guidelines on-label for certain cancers) for cancer-associated thrombosis. The SELECT-D pilot trial and ADAM VTE trial provided early data; the larger CARAVAGGIO trial (N=1,170) found apixaban non-inferior to dalteparin for recurrent VTE in cancer patients (5.6% vs. 7.9%; P<0.001 for non-inferiority) with no significant difference in major bleeding. [23] Florida Blue PA for cancer-associated thrombosis may require oncology documentation and cancer diagnosis codes in addition to the VTE workup.

Verifying Your Specific Florida Blue Plan's Coverage

Coverage details change every plan year. The only authoritative source for your coverage is the Evidence of Coverage (EOC) document and the formulary (drug list) specific to your plan and plan year. Here is how to find them:

1. Log in to your Florida Blue member account at floridablue.com and manage to "My Benefits" then "Prescription Drug Coverage."
2. Use the online formulary search tool, entering "apixaban" or "Eliquis" to see your current tier, PA status, and quantity limits.
3. Call the pharmacy benefits number on the back of your Florida Blue ID card and ask specifically: (a) Is Eliquis on my formulary? (b) What tier? (c) Is prior authorization required? (d) Is step therapy required?
4. Ask your prescriber's office to submit a PA proactively before the prescription reaches the pharmacy, to avoid a point-of-sale rejection.

The FDA maintains a drug database at DailyMed where you can verify the current labeled indications for apixaban, which supports PA documentation. [1] Discrepancies between what your prescriber writes on the PA form and the labeled indications are one of the most common reasons for initial denials.